171123 presentation biomed elements
TRANSCRIPT
Tuning Materials. Enhancing Lives. Tonny Voermans, M.Sc.
Managing Director
confidential
2
The issues of cure ▲ Drugs and medical devices become more advanced, but
still pose challenges
▲ Another issue is suboptimal handling of the device
▲ Current issues are: ▲ Complex diseases with a variety of causes and treatments
▲ Overmedication (of antibiotics)
▲ Extensive cure need due to hospitalization
confidential
3
Mission ▲ Improve the treatment options for patient and surgeon
▲ Improved working ▲ Longer efficacy (degradation)
▲ Target release
▲ Enhanced handling ▲ Better applicators
▲ Extension application areas ▲ Change functional form
confidential
4
Elements as innovation ▲ New technologies offer new treatment solutions
▲ Biopolymers are used as devices or carriers for drugs or tissues: viscosupplements and hemostasis products
▲ BioMed Elements has a technology platform to optimize the behavior of medical devices by tuning the basic elements of the polymers
confidential
5
Examples Biopolymers
Gelatine Hyaluronic Acid
Collagen
Chitosan
Alginate
Cellulose
Soy
confidential
6
Biomaterials market Market Size CAGR
Biomaterials 70 B 16%
Plastic surgery 6,5 B 14%
Orthopaedic 22 B 5%
Dental 6,6 B 7%
Hemostasis 1,5 B 4%
Tissue engineering 2,1 B 10%
The key market players are Royal DSM, Wright Medical Technology, Inc., Corbion N.V., Zimmer Biomet Holdings, Inc., Bayer AG, Carpenter Technology Corporation, Covalon Technologies Ltd., BASF SE, Invibio Ltd., Berkeley Advanced Biomaterials, Inc., and Collagen Matrix, Inc. among others.
http://www.biomatin.eu/pdf/Regional_analysis_of_the_biomaterial_market.pdf http://providencehightech.com/biomaterials-trends-forecasts/
confidential
7
BioMed Core Technology
Source Material Core Technology Spherical Submicron Particles
▲ Access to well defined spherical submicron particles
▲ Control over parameters (e.g. size, density)
▲ Patented continuous process:
▲ Upscaling is possible
▲ High consistent quality
1µm
confidential
8
Functional Forms
Suspension Powder Gel Sponge
Resorbable Hemostat Resorbable Scaffold Flowable Carrier
Application: Application: Application: Application:
Drug Carrier
Application Areas: orthobiologics, wound management, tissue engineering, medical aesthetics and cosmetics.
confidential
9
Business model ▲ Contract research and co-development:
▲ Feasibility study and product optimization
▲ Analytical study
▲ Contract manufacturing: ▲ Medical devices and half fabricates manufacturing
▲ Development own product range: ▲ Developing a range of niche products
confidential
10
Value proposition
Phase 1: Feasibility study for improved or new product
Phase 2: Proof of concept; lock in of IP
Phase 3: Upscaling of manufacturing based on BioMed expertise and manufacturing capabilities
Phase 4: Manufacturing and distribution of device
confidential
11
Current partners ▲ Netherlands: HCM Medical, Avivia, Fibriant, Leader
Biomedical and Zuyderland hospital.
▲ Europe: Mathys Medical (Switzerland), OST Developpement (France) and Sirakoss (United Kingdom).
▲ USA: Pro-Tech Design, Alamo Tissue Services, Synergy BioMedical, Celling Biosciences and Vivex Biomedical.
confidential
12
Development route ▲ Phase 1: Hemostatic range
▲ Hemostatic gel for various applications
▲ Sponge for heavy bleedings with active
confidential
13
Development route ▲ Scenario 2: Hyaluronic acid products
▲ Dermal filler
▲ Viscosupplement
confidential
14
Do’s and don’ts ▲ Be stubborn, but also look for people who are even more
stubborn
▲ Be smart on how to persuade investors
▲ Hold perspective on success; by yourself as well as from others
▲ Use network opportunities
▲ Luck = your effort + what others help you with
confidential
15
BioMed’s future ▲ Investment need for validation of haemostatic gel
▲ Set up and strengthen partner network
▲ Perform animal study for heavy bleedings product Q2 2018
▲ Market access in ENT surgery products
And what the future brings
“Tuning Materials. Enhancing Lives.”